Literature DB >> 17855575

Effect of viral load on the outcome of herpes zoster.

M L Quinlivan1, K Ayres, H Ran, S McElwaine, M Leedham-Green, F T Scott, R W Johnson, J Breuer.   

Abstract

Varicella-zoster virus (VZV) is a member of the Herpesviridae family, primary infection with which causes varicella, more commonly known as chicken pox. Characteristic of members of the alphaherpesvirus subfamily, VZV is neurotropic and establishes latency in sensory neurons. Reactivation of VZV causes herpes zoster, also known as shingles. The most frequent complication following zoster is chronic and often debilitating pain called postherpetic neuralgia (PHN), which can last for months after the disappearance of a rash. During episodes of acute zoster, VZV viremia occurs in some, but not all, patients; however, the effect of the viral load on the disease outcome is not known. Here we describe the development of a highly specific, sensitive, and reproducible real-time PCR assay to investigate the factors that may contribute to the presence and levels of baseline viremia in patients with zoster and to determine the relationship between viremia and the development and persistence of PHN. VZV DNA was detected in the peripheral blood mononuclear cells (PBMCs) of 78% of patients with acute zoster and in 9% of healthy asymptomatic blood donors. The presence of VZV in the PBMCs of patients with acute zoster was independently associated with age and being on antivirals but not with gender, immune status, extent of rash, the age of the rash at the time of blood sampling, having a history of prodromal pain, or the extent of acute pain. Prodromal pain was significantly associated with higher baseline viral loads. Viral load levels were not associated with the development or persistence of PHN at 6, 12, or 26 weeks.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17855575      PMCID: PMC2168564          DOI: 10.1128/JCM.00874-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  20 in total

Review 1.  Neurologic complications of the reactivation of varicella-zoster virus.

Authors:  D H Gilden; B K Kleinschmidt-DeMasters; J J LaGuardia; R Mahalingam; R J Cohrs
Journal:  N Engl J Med       Date:  2000-03-02       Impact factor: 91.245

Review 2.  Herpes zoster--predicting and minimizing the impact of post-herpetic neuralgia.

Authors:  R Johnson
Journal:  J Antimicrob Chemother       Date:  2001-02       Impact factor: 5.790

3.  The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: A retrospective survey in an elderly population.

Authors: 
Journal:  Eur J Pain       Date:  1999-12       Impact factor: 3.931

4.  A study of shingles and the development of postherpetic neuralgia in East London.

Authors:  Fiona T Scott; Mary E Leedham-Green; Winsome Y Barrett-Muir; Khidir Hawrami; W Jane Gallagher; Robert Johnson; Judith Breuer
Journal:  J Med Virol       Date:  2003       Impact factor: 2.327

5.  Characterization of viremia at different stages of varicella-zoster virus infection.

Authors:  C Mainka; B Fuss; H Geiger; H Höfelmayr; M H Wolff
Journal:  J Med Virol       Date:  1998-09       Impact factor: 2.327

6.  Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials.

Authors:  M J Wood; R Kay; R H Dworkin; S J Soong; R J Whitley
Journal:  Clin Infect Dis       Date:  1996-02       Impact factor: 9.079

Review 7.  Consequences and management of pain in herpes zoster.

Authors:  Robert W Johnson
Journal:  J Infect Dis       Date:  2002-10-15       Impact factor: 5.226

8.  Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation.

Authors:  A Wilson; M Sharp; C M Koropchak; S F Ting; A M Arvin
Journal:  J Infect Dis       Date:  1992-01       Impact factor: 5.226

9.  Automated detection of five human herpes virus DNAs by a set of LightCycler PCRs complemented with a single multiple internal control.

Authors:  Markus Stöcher; Gabriele Hölzl; Herbert Stekel; Jörg Berg
Journal:  J Clin Virol       Date:  2004-03       Impact factor: 3.168

10.  Peripheral blood mononuclear cells of the elderly contain varicella-zoster virus DNA.

Authors:  M E Devlin; D H Gilden; R Mahalingam; A N Dueland; R Cohrs
Journal:  J Infect Dis       Date:  1992-04       Impact factor: 5.226

View more
  13 in total

1.  Evaluation of a TaqMan Array Card for Detection of Central Nervous System Infections.

Authors:  Clayton O Onyango; Vladimir Loparev; Shirley Lidechi; Vinod Bhullar; D Scott Schmid; Kay Radford; Michael K Lo; Paul Rota; Barbara W Johnson; Jorge Munoz; Martina Oneko; Deron Burton; Carolyn M Black; John Neatherlin; Joel M Montgomery; Barry Fields
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

Review 2.  Successes and challenges in varicella vaccine.

Authors:  Orestis Papaloukas; Georgia Giannouli; Vassiliki Papaevangelou
Journal:  Ther Adv Vaccines       Date:  2014-03

Review 3.  Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer.

Authors:  Ian H Frazer; Myron J Levin
Journal:  Curr Opin Virol       Date:  2011-10       Impact factor: 7.090

4.  Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults.

Authors:  Adriana Weinberg; Jennifer Canniff; Nadine Rouphael; Aneesh Mehta; Mark Mulligan; Jennifer A Whitaker; Myron J Levin
Journal:  J Immunol       Date:  2017-06-12       Impact factor: 5.422

Review 5.  Is chickenpox so bad, what do we know about immunity to varicella zoster virus, and what does it tell us about the future?

Authors:  Anne A Gershon
Journal:  J Infect       Date:  2017-06       Impact factor: 6.072

6.  Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.

Authors:  Adriana Weinberg; Jane H Zhang; Michael N Oxman; Gary R Johnson; Anthony R Hayward; Michael J Caulfield; Michael R Irwin; James Clair; Jeffrey G Smith; Harold Stanley; Rocio D Marchese; Ruth Harbecke; Heather M Williams; Ivan S F Chan; Robert D Arbeit; Anne A Gershon; Florian Schödel; Vicki A Morrison; Carol A Kauffman; Steve E Straus; Kenneth E Schmader; Larry E Davis; Myron J Levin
Journal:  J Infect Dis       Date:  2009-10-01       Impact factor: 5.226

7.  Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors.

Authors:  G N Malavige; L Jones; A P Black; G S Ogg
Journal:  Clin Exp Immunol       Date:  2008-03-20       Impact factor: 4.330

8.  Cytotoxicity of glioblastoma cells mediated ex vivo by varicella-zoster virus-specific T cells.

Authors:  Jennifer Canniff; Andrew M Donson; Nicholas K Foreman; Adriana Weinberg
Journal:  J Neurovirol       Date:  2011-07-27       Impact factor: 3.739

9.  Differentiation between wild-type and vaccines strains of varicella zoster virus (VZV) based on four single nucleotide polymorphisms.

Authors:  L Jin; S Xu; P A C Maple; W Xu; K E Brown
Journal:  Epidemiol Infect       Date:  2017-07-27       Impact factor: 4.434

10.  IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies.

Authors:  G N Malavige; L T Rohanachandra; L Jones; L Crack; M Perera; N Fernando; D Guruge; G S Ogg
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.